Editas Medicine(EDIT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EDIT Editas Medicine

Pre-Mkt 08-17 05:29:05 EDT

2.82

+0.01

+0.36%

盘前2.85

+0.03+1.21%

04:19 EDT

High2.85	Low2.72	Vol1.48M
Open2.81	D1 Closing2.81	Amplitude4.63%
Mkt Cap431.46M	Tradable Cap399.98M	Total Shares153.00M
T/O4.13M	T/O Rate1.04%	Tradable Shares141.84M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"EDIT","market":"US","secType":"STK","nameCN":"Editas Medicine","latestPrice":2.82,"timestamp":1786737600000,"preClose":2.81,"halted":0,"volume":1478046,"hourTrading":{"tag":"盘前","latestPrice":2.8542,"preClose":2.82,"latestTime":"04:19 EDT","volume":2,"amount":5.7084,"timestamp":1786954779296,"change":0.0342,"changeRate":0.012128,"amplitude":0},"delay":0,"changeRate":0.0035587188612098883,"floatShares":141837682,"shares":153000000,"eps":-0.730719,"marketStatus":"Pre-Mkt","change":0.01,"latestTime":"08-17 05:29:05 EDT","open":2.81,"high":2.845,"low":2.715,"amount":4126056.4566336,"amplitude":0.046263,"askPrice":3.1,"askSize":10,"bidPrice":2.51,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.730719,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1786973400000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.82,"preHourTrading":{"tag":"盘前","latestPrice":2.8542,"preClose":2.82,"latestTime":"04:19 EDT","volume":2,"amount":5.7084,"timestamp":1786954779296,"change":0.0342,"changeRate":0.012128,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":2.84,"preClose":2.82,"latestTime":"19:34 EDT","volume":16341,"amount":46210.925,"timestamp":1786750451027,"change":0.02,"changeRate":0.007092,"amplitude":0.007092},"volumeRatio":0.9271498670266077,"impliedVol":1.2441,"impliedVolPercentile":0.68},"requestUrl":"/m/hq/s/EDIT","defaultTab":"news","newsList":[{"id":"2658593567","title":"Editas Medicine, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658593567","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658593567?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:59","pubTimestamp":1786363182,"startTime":"0","endTime":"0","summary":"Editas Medicine, Inc. reports results for the quarter ended June 30 - Earnings SummaryEditas Medicine, Inc.EDIT.OQreported a quarterly adjusted loss of 15 cents per share for the quarter ended June 30","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL8N4470RH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","EDIT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657262941","title":"Editas Medicine Director Ellinor Patrick Thomas II Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2657262941","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657262941?lang=en_us&edition=fundamental","pubTime":"2026-08-08 05:16","pubTimestamp":1786137389,"startTime":"0","endTime":"0","summary":"Editas Medicine director Ellinor Patrick Thomas II files initial beneficial ownership statementEditas Medicine filed a Form 3 showing director Ellinor Patrick Thomas II as a reporting owner, dated Aug. 6.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 07, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL63cxB4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDIT","BK4556","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657644491","title":"Editas Medicine, Inc. Expected to Post a Loss of 27 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657644491","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657644491?lang=en_us&edition=fundamental","pubTime":"2026-08-07 22:33","pubTimestamp":1786113186,"startTime":"0","endTime":"0","summary":"Editas Medicine, Inc. <EDIT.OQ> expected to post a loss of27cents a share - Earnings PreviewEditas Medicine, Inc.EDIT.OQEDIT.Ois expected to  show a fall in quarterly revenue when it reports  results ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4441OR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDIT","BK4556","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657560633","title":"Intellia Therapeutics Q2 Collaboration Revenue Falls, Net Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2657560633","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657560633?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:20","pubTimestamp":1786015252,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics Q2 collaboration revenue falls, net loss widensOverviewU.S. gene editing firm's Q2 collaboration revenue fell yr/yr due to lower Regeneron revenueQ2 net loss widened from prior y","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430JC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861558580.USD","NTLA","LU2237438978.USD","BK4139","LU1917777945.USD","LU1974910355.USD","IBB","LU0889565916.HKD","LU0289739699.SGD","LU0109394709.USD","LU2023250504.SGD","BK4611","LU0114720955.EUR","LU2089984988.USD","LU0823434583.USD","CRSP","LU1861559042.SGD","TBXU","LU0058720904.USD","IBBQ","LU2362540622.SGD","LU2362541513.USD","BBH","EDIT","LU2106854487.HKD","BK4556","LU0320765992.SGD","REGN","LU2468319806.SGD","LU0823416689.USD","BK4585","LU2362541273.HKD","LU0823434740.USD","BK4535","PGEN","BK4588","ARKG","LU0053666078.USD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657687268","title":"Analysts Are Bullish on Top Healthcare Stocks: MannKind (MNKD), Disc Medicine (IRON)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657687268","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657687268?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:40","pubTimestamp":1786012820,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on MannKind (MNKD), Disc Medicine (IRON) and Editas Med...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-mannkind-mnkd-disc-medicine-iron-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-mannkind-mnkd-disc-medicine-iron-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IRON","LU0053671581.USD","MNKD","BK4556","EDIT","BK4584","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657508570","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ginkgo Bioworks Holdings (DNA), Exelixis (EXEL) and Editas Medicine (EDIT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657508570","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657508570?lang=en_us&edition=fundamental","pubTime":"2026-08-06 09:20","pubTimestamp":1785979213,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ginkgo Bioworks Holdings (DNA), Exelixis (EXEL) and Editas Medici...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-ginkgo-bioworks-holdings-dna-exelixis-exel-and-editas-medicine-edit-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-ginkgo-bioworks-holdings-dna-exelixis-exel-and-editas-medicine-edit-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4121","BK4109","DNA","EDIT","LU0128526141.USD","LABU","BK4556","BK4581","EXEL","XLV","BK4139","XBI","BK4532","BK4137","HCSG","BK4585","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657660574","title":"Editas Medicine Q2 2026 earnings: Deferred revenue and restructuring narrow the loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2657660574","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657660574?lang=en_us&edition=fundamental","pubTime":"2026-08-06 05:40","pubTimestamp":1785966043,"startTime":"0","endTime":"0","summary":"Editas Medicine’s Q2 2026 collaboration and other R&D revenue rose to $11.9 million from $3.6 million, while net loss narrowed to $18.2 million, or $0.15 per share, from $53.2 million, or $0.63 per share. The improvement was driven mainly by BMS-related deferred revenue and a $1.3 million restructuring benefit versus a $26.1 million charge, even as R&D expense increased to $20.2 million for EDIT-401. Cash reached $211.6 million after a $125.0 million gross equity offering, with runway expected into the second half of 2028.","market":"other","thumbnail":"https://resource.tradingkey.com/cdn/images/article/news/stock3.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cdn/images/article/news/stock3.jpg"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/earnings/262079883-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VOTE","FEBU","JOYT","RGLO","VGFPF","EDIT","DECU","PMDE","GXDW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657757962","title":"Editas Medicine Strengthens Board With New Cardiology Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2657757962","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657757962?lang=en_us&edition=fundamental","pubTime":"2026-08-06 05:07","pubTimestamp":1785964075,"startTime":"0","endTime":"0","summary":"An announcement from Editas Medicine ( ($EDIT) ) is now available. On August 3, 2026, Editas Medicine director Elliott Levy, M.D., resigned from th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/editas-medicine-strengthens-board-with-new-cardiology-director?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/editas-medicine-strengthens-board-with-new-cardiology-director?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EDIT","BK4556","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657242573","title":"Editas Medicine Q2 EPS $(0.15) Beats $(0.27) Estimate, Sales $11.900M Beat $2.800M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657242573","media":"Benzinga Earnings","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657242573?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:37","pubTimestamp":1785962255,"startTime":"0","endTime":"0","summary":"Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.27) by 44.44 percent. This is a 76.19 percent increase over losses of $(0.63) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60974182/editas-medicine-q2-eps-0-15-beats-0-27-estimate-sales-11-900m-beat-2-800m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657752095","title":"Editas Medicine Q2 Net Loss Narrows and Beats Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657752095","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657752095?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:11","pubTimestamp":1785960676,"startTime":"0","endTime":"0","summary":"Editas Medicine Q2 net loss narrows and beats estimatesOverviewUS gene editing firm's Q2 net loss narrowed and beat analyst expectationsCollaboration and other R&D revenue more than tripled yr/yr to $","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421AG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRSP","TRDA","BK4588","KYMR","BK4585","BK4556","BK4139","BK4611","ARKG","EDIT","LU1861559042.SGD","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657527677","title":"Editas Medicine Q2 Net Income USD -18.23 Million Vs. IBES Estimate USD -27 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657527677","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657527677?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:02","pubTimestamp":1785960121,"startTime":"0","endTime":"0","summary":"BRIEF-Editas Medicine Q2 Net Income USD -18.23 Million Vs. IBES Estimate USD -27 MillionAug 05  - Editas Medicine Q2 operating expenses USD 30.444 million.Q2 operating income USD -18.554 millionQ2 basic EPS USD -0.15Q2 collaboration and other research and development revenue USD 11.9 millionQ2 EPS USD -0.15","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nPLX0ZL5LD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EDIT","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657342527","title":"Editas Medicine Announces Second Quarter 2026 Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657342527","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657342527?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:01","pubTimestamp":1785960062,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nTUA94XR28:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EDIT","BK4556","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657152736","title":"Editas Medicine Q2 Basic EPS USD -0.15","url":"https://stock-news.laohu8.com/highlight/detail?id=2657152736","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657152736?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:01","pubTimestamp":1785960061,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nPLX0ZL5LD:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EDIT","BK4139","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657562013","title":"Editas Medicine Names Patrick Ellinor to Board, Elliott Levy to Step Down","url":"https://stock-news.laohu8.com/highlight/detail?id=2657562013","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657562013?lang=en_us&edition=fundamental","pubTime":"2026-08-05 05:00","pubTimestamp":1785877250,"startTime":"0","endTime":"0","summary":"Editas Medicine names Patrick Ellinor to board, Elliott Levy to step downEditas Medicine appointed Patrick T. Ellinor to its board, effective Aug. 6, 2026.Ellinor is executive director of the Mass Gen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL93Xk7s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4588","BK4139","IE00BN0W2T93.GBP","NDAQ","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","EDIT","SG9999014013.SGD","SG9999014005.SGD","BK4112","BK4585","LU0314104364.USD","IE00BN0W2V16.EUR","LU2095319765.USD","IE00BN0W2W23.USD","SG9999014039.USD","IE00BKPKM429.USD","BCDF","BK4556","SG9999014021.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657956195","title":"Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.d., Ph.d.","url":"https://stock-news.laohu8.com/highlight/detail?id=2657956195","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657956195?lang=en_us&edition=fundamental","pubTime":"2026-08-05 04:15","pubTimestamp":1785874500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nTUA1V7NDY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EDIT","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651195898","title":"Genflow Appoints Gad Berdugo as Independent Non-executive Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2651195898","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651195898?lang=en_us&edition=fundamental","pubTime":"2026-07-13 14:00","pubTimestamp":1783922433,"startTime":"0","endTime":"0","summary":"Genflow appoints Gad Berdugo as independent non-executive chairmanGenflow named Gad Berdugo as independent non-executive chairman in January 2026.Berdugo brings more than 30 years of biotech leadershi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nNDL2hDq84:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDIT","GENF.UK","BK4556","BK4139","BK5083"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644031775","title":"Editas Medicine Shareholders Back Board, Pay and Auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=2644031775","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644031775?lang=en_us&edition=fundamental","pubTime":"2026-06-19 05:50","pubTimestamp":1781819405,"startTime":"0","endTime":"0","summary":"An announcement from Editas Medicine ( ($EDIT) ) is now available. At its June 17, 2026 annual meeting, Editas Medicine stockholders elected Bernad...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/editas-medicine-shareholders-back-board-pay-and-auditor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/editas-medicine-shareholders-back-board-pay-and-auditor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4556","EDIT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644036719","title":"Editas Medicine shareholders elect Connaughton, Levy as Class I directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2644036719","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644036719?lang=en_us&edition=fundamental","pubTime":"2026-06-19 04:29","pubTimestamp":1781814564,"startTime":"0","endTime":"0","summary":"Editas Medicine held its 2026 annual stockholders meeting on June 17, 2026.Stockholders backed the board’s director slate, resulting in Bernadette Connaughton and Elliott Levy, M.D., serving as Class I directors through 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL8q1ZRv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDIT","BK4556","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639661684","title":"Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2639661684","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639661684?lang=en_us&edition=fundamental","pubTime":"2026-05-29 04:01","pubTimestamp":1779998460,"startTime":"0","endTime":"0","summary":"ir@editasmed.com. media@editasmed.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/28/3303236/0/en/Editas-Medicine-Announces-Updated-Presentation-Time-for-Upcoming-Investor-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EDIT","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638768210","title":"Editas Medicine preclinical data ‘looks highly supportive,’ says Evercore ISI","url":"https://stock-news.laohu8.com/highlight/detail?id=2638768210","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638768210?lang=en_us&edition=fundamental","pubTime":"2026-05-28 00:33","pubTimestamp":1779899629,"startTime":"0","endTime":"0","summary":"After Editas Medicine (EDIT) presented new preclinical data for EDIT-401, its lead in vivo development candidate, in an oral presentation at the Eu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/editas-medicine-preclinical-data-looks-highly-supportive-says-evercore-isi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/editas-medicine-preclinical-data-looks-highly-supportive-says-evercore-isi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EDIT","BK4556","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.editasmedicine.com","stockEarnings":[{"period":"1week","weight":-0.0208},{"period":"1month","weight":-0.0724},{"period":"3month","weight":0.0763},{"period":"6month","weight":0.6023},{"period":"1year","weight":-0.0473},{"period":"ytd","weight":0.3756}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0503},{"period":"6month","weight":0.1387},{"period":"1year","weight":0.2037},{"period":"ytd","weight":0.1385}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.048743},{"month":2,"riseRate":0.5,"avgChangeRate":0.075357},{"month":3,"riseRate":0.363636,"avgChangeRate":-0.053873},{"month":4,"riseRate":0.454545,"avgChangeRate":-0.002841},{"month":5,"riseRate":0.545455,"avgChangeRate":0.014988},{"month":6,"riseRate":0.545455,"avgChangeRate":0.075904},{"month":7,"riseRate":0.636364,"avgChangeRate":0.013826},{"month":8,"riseRate":0.636364,"avgChangeRate":0.041355},{"month":9,"riseRate":0.2,"avgChangeRate":-0.076361},{"month":10,"riseRate":0.4,"avgChangeRate":-0.058936},{"month":11,"riseRate":0.5,"avgChangeRate":0.071042},{"month":12,"riseRate":0.3,"avgChangeRate":0.023099}],"exchange":"NASDAQ","name":"Editas Medicine","nameEN":"Editas Medicine"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Editas Medicine(EDIT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Editas Medicine(EDIT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Editas Medicine,EDIT,Editas Medicine股票,Editas Medicine股票老虎,Editas Medicine股票老虎国际,Editas Medicine行情,Editas Medicine股票行情,Editas Medicine股价,Editas Medicine股市,Editas Medicine股票价格,Editas Medicine股票交易,Editas Medicine股票购买,Editas Medicine股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Editas Medicine(EDIT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Editas Medicine(EDIT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction